Efficacy and safety of topical steroid/antibiotic association treatments following phacoemulsification cataract extraction - ND

SIFI0 个研究点目标入组 240 人开始时间: 2006年8月30日最近更新: 2012年3月19日

试验速览

暂无简介。

•1. Subjects having to undergo phacoemulsification cataract extraction with intra-ocular lens implantation; 2. Able and willing to give informed consent; 3. Age 40; 4. Any race and sex; 5. Willing and able to attend required study visits
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. History of ocular inflammatory diseases, ocular herpes infection, iritis, uveitis or Sjogren s syndrome; 2. Treatment for an external ocular infection within 1 month prior to study entry; 3. Concomitant ocular pathology including one of the following ocular infections, uveitis, iritis, iridocyclitis, glaucoma, proliferative diabetic retinopathy ; 4. Intraocular pressure 24 mmHg; 5. Ocular surgery in the affected eye within 12 months before the beginning of the study; 6. Laser treatment in the affected eye within 6 months before the beginning of the study; 7. Known or suspected allergy to ocular preservatives, phenylacetic acid derivatives, aminoglycosides and steroids; 8. Subjects currently participating in another clinical study or who have participated in a clinical study in the preceding 30 days; 9. Intake of any pharmaceutical form of antihistamines, decongestants, steroids or non-steroidal anti-inflammatory agents within 15 days prior to study entry 10. Use of ocular medication other than artificial tears; 11. Pregnant or nursing women or inadequate birth control methods applicable to female of childbearing potential only ; 12. Monophthalmic

发起方